Drug Trial Radar · NCT07722312
S243249 Monotherapy in Patients With Relapsed or Refractory Acute Leukemia With a KMT2A or NUP98 Translocation or Relapsed or Refractory AML With NPM1c Mutation
Last checked: Nov 19, 2026Latest source record: Nov 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
80
Planned (sponsor's estimate)
Start
Feb 1, 2027
Primary completion
Aug 11, 2029
Study completion Aug 25, 2030
Sponsor
- Lead sponsor
- ServierIndustry
- Sponsor type
- Industry
- First posted
- Jul 23, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The objective of this study is to establish the efficacy, safety, and tolerability of S243249 and to establish the recommended phase 2 dose (RP2D) of S243249 monotherapy in participants with relapsed/refractory (R/R) acute leukemia with select mutations. Phase 1 dose optimization will determine the RP2D to be used in Phase 2 dose expansion. The study will include a screening period, a treatment period consisting of continuous 28-day cycles of treatment, a safety follow-up period and a long-term follow-up period. Participants may undergo blood tests, electrocardiogram (ECG), bone marrow aspirations, vital sign checks, questionnaires, and physical exams.
Conditions
- Relapsed or Refractory Acute Leukemia
- Relapsed or Refractory Acute Myeloid Leukemia
Interventions
S243249 600mgDrug
Taken twice daily by mouth
S243249 400mgDrug
Taken twice daily by mouth
S243249 450mgDrug
Taken twice daily by mouth
S243249 300mgDrug
Taken twice daily by mouth
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of Adverse Events (AEs)Time frame: Through Safety Follow-up (Approximately 3 years)
- Severity of AEsTime frame: Through Safety Follow-up (Approximately 3 years)
- Number of Serious Adverse Events (SAEs)Time frame: Through Safety Follow-up (Approximately 3 years)
- Number of changes in laboratory valuesTime frame: Through Safety Follow-up (Approximately 3 years)
- Number of changes in electrocardiogram (ECG)Time frame: Through Safety Follow-up (Approximately 3 years)
- Number of changes in vital signsTime frame: Through Safety Follow-up (Approximately 3 years)
- Number of AEs leading to dose interruptionTime frame: Through Safety Follow-up (Approximately 3 years)
- Number of AEs leading to dose modificationTime frame: Through Safety Follow-up (Approximately 3 years)
- Number of AEs leading to dose delaysTime frame: Through Safety Follow-up (Approximately 3 years)
- Number of AEs leading to permanent treatment discontinuationTime frame: Through Safety Follow-up (Approximately 3 years)
- Complete remission (CR) + Complete remission with partial recovery of hematology (CRh) rateTime frame: Through Long-term Follow-up (Approximately 5 years)
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.